(Nasdaq: ADIL) Tops Today's Biopharma Watchlist (Low Float - 5 Key Potential Catalysts)

A relatively unknown player in the biopharma space

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (Nasdaq: ADIL) Tops Today's Biopharma Watchlist (Low Float - 5 Key Potential Catalysts) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* March 3rd Greetings, Friend! A relatively unknown player in the biopharma space is steadily working towards treatments for alcohol use disorder (“AUD”). Its emerging therapies are specifically built around improving patient adherence and clinical outcomes, positioning the company to challenge a market estimated at more than $1.1Bn. Initial signs indicate this group could be establishing a new benchmark in one of healthcare’s most neglected segments. Couple that with a very small float of under 1Mn shares and an analyst target projection implying potential triple-digit upside, and this lesser-known Nasdaq name has moved to the top of our watchlist: Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. Adial is currently planning to conduct a new Phase 3 clinical trial program for the treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary diagnostic genetic test. Alcohol Use Disorder is a Major Publish Health Concern In The U.S. Failure to help people with AUD is a major health, social and financial problem. In the U.S. alone, an estimated 30Mn people SUFFER FROM AUD, resulting in significant health, social and financial costs. Excessive Alcohol Use: Costs U.S. economy approximately $250Bn annually 50% increase in prevalence from 2002 to 2013 Contributes to over 200 different diseases 31% of driving fatalities due to alcohol use Despite these enormous costs, just over 7% seek help, but less than 5% AUD cases are treated by a health care practitioner. A Significant Segment of the Market Not Being Address in the U.S. The vast majority of patients that have AUD remain undiagnosed and untreated, creating a large market opp. for a product that can address patient needs. Excessive Alcohol Use accounts for ~5.3% of deaths worldwide and ~5.1% of disease worldwide. The Lancet reports that alcohol is the number one risk factor for death globally among both men and women ages 15 to 49 years. Due to limitations of existing therapies, over 95% of people with AUD do not receive medical treatment. AD04 is Designed to Meet the Market Need A new approach for patients who desire to control drinking but cannot or will not undertake existing treatment options. Reduction of Heavy Drinking Target Indication Ends need for abstinence, a major hurdle in starting & continuing pharmacologic therapy. Good Safety Profile, High Tolerability Brings 20+ year record of acute clinical use with positive safety and tolerability profile. Lowers the Stigma of AUD and Empowers the Patient Takes treatment from detox clinics & group therapy - - realizes patients’ desire of reduced drinking. Oral Daily Dosing (twice-a-day now, once-a-day expected) Patient compliance, ease of use & increased effect. Genetic Tests for Precision Medicine Genetic biomarker test identifies the patients likely to benefit from AD04. The Company's Upcoming Steps Finalize plans to begin Phase 3 Clinical Trial. Finalize Clinical Development Plan since receiving FDA feedback from EOP2 meeting Protocol design Aligned FDA endorsed adaptive trial design, biomarker stratification, and target population Endpoints Confirmed FDA validated primary endpoint of zero heavy drinking days during months 5-6 Biomarker Strategy Affirmed FDA supported AG+ targeted therapy approach for biomarker-positive patients Statistical Framework Aligned FDA approved interim analyses, alpha control methodology, and DMC structure Phase 3 Cleared Regulatory alignment secured for advancement to registrational trial Recently published FDA Policy Directive May reduce Pivotal Trial Burden from Two Studies to One Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission for AD04 Manufacturing drug product needed for clinical trial Advancing Discussions with Potential Strategic Partners Phase 3 clinical program funding Commercialization of AD04 assuming a successful regulatory outcome Find Source And Key Info Here: ADIL Website. ADIL Presentation. ----- Consider Paying Close Attention To Banzai International, Inc. (NASDAQ: BNZI) For Five Compelling Reasons... #1. A Low Float This Size Could Create The Potential For A Volatile Environment. Based on ADIL's low float of approximately 858.25k shares, volatility potential could become a significant factor in a blink. No. 2 - An Analyst $8 Target Is On Full Display. Maxim Group analyst, Jason McCarthy has slapped a $8 price target on ADIL. From its closing valuation on Monday, this target suggests a potential upside of over 200%. No. 3 - Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden From Two Studies To One. The FDA’s new default allowing a single adequate, well-controlled pivotal study plus confirmatory evidence materially improves the regulatory outlook for Adial Pharmaceuticals and its lead asset AD04. Adial had previously contemplated two Phase 3 trials, the most capital-intensive part of development. Under the modernized framework, a one-study path could significantly cut Phase 3 costs, shorten timelines, and accelerate NDA submission while maintaining rigorous standards.  Management views this evidentiary shift as potentially transformative, enhancing AD04’s strategic and economic profile as a late-stage, genetically targeted treatment for Alcohol Use Disorder. No. 4 - Adial Pharmaceuticals Announces Publication Of International PCT Patent Application To Protect Core Assets And Extend IP Exclusivity To At Least 2045. Adial Pharmaceuticals has announced publication of its international PCT patent application for AD04, its lead genetically targeted serotonin-3 receptor antagonist for Alcohol Use Disorder in heavy-drinking patients. Filed in July 2024, the patent is expected, once granted, to protect Adial’s core AD04 assets through at least 2045, meaningfully extending commercial exclusivity. The application reflects an in-depth reanalysis of clinical data identifying patient populations particularly responsive to ondansetron-based therapy, reinforcing the precision-medicine positioning of AD04. Company CEO, Cary Claiborne, highlighted that strengthened intellectual property, guided by new patent counsel, bolsters Adial’s portfolio and supports ongoing planning for the next phase of clinical development. No. 5 - A Potential Healthy Reversal Could Be Approaching For ADIL. Technical analysis reveals ADIL has several oversold indicators, suggesting a possible reversal setup may be developing. At close on Monday, ADIL had a 9 and 14-Day Relative Strength Index both below 19% and a 14-Day Raw Stochastic below 17%. These technical levels suggest a profile that may be currently undervalued. ----- Coverage is a "Go" on Adial Pharmaceuticals, Inc. (Nasdaq: ADIL). When updates are available, we'll get them out to you quickly. Talk soon. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 03/02/2026 and ending on 03/03/2026 to publicly disseminate information about (ADIL:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). These Funds were part of the seventy seven thousand five hundred USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (ADIL:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/adil-snsyo/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice